|

ABSK043 single agent Clinical Trials

1 actively recruiting trial

Also known as: ABSK043

Pipeline

Phase 2: 1

Top Sponsors

  • University Health Network, Toronto1

Indications

  • Sarcoma1
  • Cancer1

Other1 trial

A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.